Controlled expansion and maturation of immunoselected stem cells for clinical use

D. E. Van Epps*, J. Bender, S. Smith, M. Loudovaris, K. Unverzagt, X. Qiao, A. Smith, P. Law, S. Williams

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Studies of CD34 cells from different sources indicate marked differences in number and content in bone marrow, mobilized peripheral blood and fetal cord blood. Comparison of mononuclear cells from 3 different mobilization regimens using G-CSF and/or cytoxan/VP16 (Chemo) indicated that the combination of G-CSF and Chemo yielded the highest percentage of CD34 cells. This was followed by marrow, cord blood, chemo, and then G-CSF mobilized blood. CD34 subset analysis showed higher percentages of CD19+, 34+ cells in marrow and CD38-, 34+ cells in cord blood. The Isolex® magnetic bead selection technology was used to efficiently harvest CD34 cells from all sources. This selection significantly reduced T cells and gave purities of CD34 cells averaging >78% with all CD34 cell sources. Culture of CD34 cells in gas permeable blood bags under serum free conditions resulted in significant proliferation and production of neutrophil and platelet progenitors. These studies show that progenitor cells can be produced in vitro under conditions applicable to patient treatment.

Original languageEnglish (US)
Pages (from-to)S6-S7
JournalBone Marrow Transplantation
Issue numberSUPPL. 1
StatePublished - 1994

ASJC Scopus subject areas

  • Hematology
  • Transplantation


Dive into the research topics of 'Controlled expansion and maturation of immunoselected stem cells for clinical use'. Together they form a unique fingerprint.

Cite this